The role of cytokines in the regulation of NK cells in the tumor environment

• Published in: Cytokine (Philadelphia, Pa.) Pa.), 2019-05, Vol.117, p.30-40
• Main Authors: Konjević, Gordana M., Vuletić, Ana M., Mirjačić Martinović, Katarina M., Larsen, Annette K., Jurišić, Vladimir B.
• Format: Article
• Language: English
• Subjects: Cytokines; Cytotoxicity; Immunotherapy; NK cells; Tumors
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1016/j.cyto.2019.02.001

•Cytokines are pivotal for the maturation, activation and survival of NK cells.•Interleukins (IL)-2, IL-12, IL-15, IL-18, IL-21 and type I interferons positively regulate NK cell function.•Other cytokines, such as IL-23 and IL-27, may enhance or suppress NK cell function depending on the context.•In the tumor microenvironment, TGFβ, IL-10 and IL-6 suppress NK cell activity directly or indirectly. Natural killer (NK) cells are innate lymphoid cells that are important effectors in the first line of defense toward transformed cells. This is mediated both by direct cytotoxic mechanisms and by production of immunoregulatory cytokines. Recent evidence has shown that NK cells also display memory, similar to the cells of the adaptive immune system. Cytokines are pivotal for the maturation, activation and survival of NK cells. Interleukins (IL)-2, IL-12, IL-15, IL-18, IL-21 and type I interferons positively regulate NK cell function, either independently or in cooperation, whereas other cytokines, such as IL-23 and IL-27, may enhance or suppress NK cell function depending on the context. In the tumor microenvironment, TGFβ, IL-10 and IL-6 suppress NK cell activity not only directly, but also indirectly, by affecting immunosuppressive cells and by antagonizing the effect of stimulatory cytokines, thereby dampening the antitumor response of NK cells and promoting subsequent tumor evasion and progression. Increased understanding of the NK cell response to cytokines has provided a better understanding of their impaired function in tumors which may aid in the development of novel immunotherapeutic strategies to enhance NK cell responses in cancer patients.